Ann: Appendix 4D, page-29

Hey Team,

Well in any case that has to be the most detailed honest cleansing report ever to come out of this enterprise.Really what to expect after years of mismanagement and virtually ZERO governance.
Its a miracle this company wasn't put some time ago in Chapter 11 with the cavalier type corporate behaviour & related party transactions accompanied.
Look even if there is yet another dilutive financing , which seems very much on the cards, it will mean survival & a way forwards. Better to own 1% of a sustainable business than 2% of nothing.
The statement below is encouraging & welcome news in what is still a very difficult & unpredictable time for the company.
Its very easy to understand the sell side sentiment & hugely tough to buy in now..but the potential upside from the "chump change" MCap of today is large if & when the company secure operating funds going forwards.

"Known trends in the industry that we believe will have a material favorable impact on our revenue include a shift in the focus of large pharmaceutical and biotechnology companies’ product development activities to biologic therapies, an emphasis within health-care providers to patient self-administration and a growing demand for passive safety for injectable drug delivery. There has been a marked shift in the product development activities of large customers toward biologic therapies, and the majority of therapies in the pipeline of large pharmaceutical and biotechnology companies are complex biologic therapies. The characteristics of many of these therapies (including, for example, large dose volumes and increased viscosity) necessitates administration by injection using innovative injectable drug delivery systems such as our products. We believe that we are well-positioned to meet what we expect to be a growing demand for innovative injectable drug delivery systems in light of the focus on biologic therapies. Concurrently with the shift toward biologic therapies is an emphasis towards patient self-administration. Patient self-administration is viewed as a growing trend in order to reduce demand pressure on the health-care system as well as reducing costs, especially for treatment of chronic illnesses. Devices suitable for self-administration of injectable therapies need to be safe and intuitive to use. We believe that our products are well suited for safe and intuitive patient self-administration of injectable therapies."

Now off for a game at the Wainui Club north of Auckland on a fresh breezy day.
Investing or rather speculating in Unilife has been like playing a golf course with nearly every hole against the wind...
Time to reach the down wind part of the course soon.

Best,
S.G